New Pancreatic Cancer Vaccine Sparked Immune Responses in 99% of Patients
An experimental mRNA vaccine targeting KRAS mutations triggered immune responses in 99% of pancreatic cancer patients in recent Phase 2 study results.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
A new experimental vaccine targeting rogue genes linked to 90 percent of pancreatic cancers has demonstrated the ability to trigger immune responses in 99 percent of patients. According to coverage from Oncodaily and ScienceAlert, Cosimo Commisso reported that this personalized KRAS vaccine generated these significant immune responses. The vaccine utilizes mRNA technology to harness the power of the immune system. While the response rate was high, Inkorr reports that the vaccine triggered strong T-cell responses in nearly all patients but failed to delay relapse. The treatment specifically targets KRAS mutations, which are common drivers in the development of pancreatic tumors.
Multiple outlets are tracking the development and presentation of this data. GlobeNewswire and Yahoo Finance UK report that Elicio Therapeutics is scheduled to present results from the Phase 2 AMPLIFY-7P trial at the SITC 2026 Annual Meeting. Investing.com further confirms that Elicio will present KRAS vaccine data at this cancer conference. Additionally, Health and Me and IFLScience have emphasized the vaccine's ability to target the specific genetic mutations linked to the vast majority of these cancer cases, while Medical Xpress notes the investigational nature of the study regarding KRAS mutations.
Contextual reports from Nature and AllSci provide insight into the broader scientific landscape of these treatments. Nature describes the design of a tumor landscape-modifying vaccine that utilizes a unique TLR2/6 agonist for refractory pancreatic cancer. Meanwhile, a team from Yonsei has shown that a dual-antigen KRAS/WNT5a vaccine can enhance pancreatic cancer immunotherapy. These developments are part of a wider trend in mRNA vaccine application, as highlighted by NPR, which is exploring what the latest advancements in mRNA technology mean for the future of cancer treatment and personalized medicine.
Future developments center on the official presentation of the AMPLIFY-7P Phase 2 results at the upcoming SITC 2026 Annual Meeting. Observers and medical professionals will be looking for more detailed data from Elicio Therapeutics to understand why the strong T-cell responses reported by Inkorr did not translate into a delay in patient relapse. Further research into dual-antigen vaccines, such as the KRAS/WNT5a approach mentioned by AllSci, may also provide a path forward for enhancing the efficacy of these immunotherapies in treating refractory pancreatic cancer cases.
Synthesized by PULSE from the headlines below under a strict no-invention contract. Updated 13d ago.
Quick answers
What percentage of patients responded to the vaccine?
The vaccine sparked immune responses in 99% of patients.
Which company is presenting the Phase 2 AMPLIFY-7P results?
Elicio Therapeutics is presenting the results at the SITC 2026 Annual Meeting.
Did the vaccine prevent cancer relapse?
According to Inkorr, while it triggered strong T-cell responses, it failed to delay relapse.
Coverage (14)
- A New Experimental Vaccine Targets Rogue Genes Linked To 90 Percent Of Pancreatic Cancers IFLScience · 19d ago
- Pancreatic Cancer Vaccine Triggers Strong T-Cell Response in Nearly All Patients but Fails to Delay Relapse Inkorr · 19d ago
- What the latest on mRNA vaccines means for cancer NPR · 19d ago
- Designing a tumor landscape-modifying vaccine with a unique TLR2/6 agonist for refractory pancreatic cancer Nature · 19d ago
- New Pancreatic Cancer Vaccine Triggers Immune Response In 99% Of Patients Health and Me · 19d ago
- Elicio to present KRAS vaccine data at cancer conference Investing.com · 19d ago
- Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting GlobeNewswire · 19d ago
- Yonsei team show dual-antigen KRAS/WNT5a vaccine enhances pancreatic cancer immunotherapy AllSci · 19d ago
- Cosimo Commisso: Personalized KRAS Vaccine Generates Immune Responses in 99% of Patients Oncodaily · 19d ago
- New hope for pancreatic cancer patients with early mRNA vaccine results The Australian · 19d ago
- Lifesaving vaccines: Using KRAS to harness the power of the immune system The Cancer Letter · 19d ago
- Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting Yahoo Finance UK · 19d ago
- Investigational vaccine generates immune response to KRAS mutations in pancreatic cancer study Medical Xpress · 19d ago
- New Pancreatic Cancer Vaccine Sparked Immune Responses in 99% of Patients ScienceAlert · 19d ago
Topics
Related trends
Pancreatic cancer mystery deepens as researchers make unexpected discovery
Recent studies reveal unexpected biological differences and immune cell behaviors in pancreatic cancer.
Richard Sterban, the Bass Singer for the Oak Ridge Boys, Dies at 83
Richard Sterban, the distinctive bass singer of the legendary country and gospel group The Oak Ridge Boys, has died at 83.
Experimental drug eliminates 75% of aggressive pancreatic tumors and enhances immune system memory
MedPacto reported that its experimental drug MP010 eliminated 75% to 87.5% of aggressive pancreatic tumors in mice.
Gastroenterologist Warns: Indigestion After Meals May Signal Early Pancreatic Cancer
A gastroenterologist's warning that post-meal indigestion could signal early pancreatic cancer is driving a wave of awareness coverage across U.S. and Australian outlets.
Local woman starts groundbreaking new pancreatic cancer treatment
A local woman begins a groundbreaking new pancreatic cancer treatment as emerging therapies gain wider media attention.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.